A phase 2 dose-ranging study of subcutaneous tabalumab for...

A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate

Genovese, M. C., Lee, E., Satterwhite, J., Veenhuizen, M., Disch, D., Berclaz, P.-Y., Myers, S., Sides, G., Benichou, O.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
72
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2012-202864
Date:
September, 2013
File:
PDF, 565 KB
english, 2013
Conversion to is in progress
Conversion to is failed